Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.32 |
| ▸ | CDK2 | P24941 | 4/20 | 0.32 |
| ▸ | GSK3B | P49841 | 4/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25187762 | 1.00 | LMNA (0.33) | LMNAGABRA1ALDH1A1CCNE1CDK2 | |
| SCHEMBL25187572 | 1.00 | LMNA (0.33) | LMNAGABRA1ALDH1A1CCNE1CDK2 | |
| SCHEMBL22310682 | 0.87 | LMNA (0.38) | LMNAGABRA1ALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL23010377 | 0.83 | ALDH1A1 (0.35) | GABRA1ALDH1A1CYP3A4FFAR3 | |
| SCHEMBL9991824 | 0.82 | — | — | |
| SCHEMBL21427860 | 0.82 | GABRA1 (0.30) | GABRA1 | |
| SCHEMBL8230855 | 0.80 | CCNE1 (0.35) | GABRA1ALDH1A1CCNE1CDK2GSK3B | |
| SCHEMBL21427823 | 0.79 | — | — | |
| SCHEMBL21427834 | 0.77 | CCNE1 (0.32) | LMNAGABRA1CCNE1CDK2GSK3B | |
| SCHEMBL31024267 | 0.74 | GABRA1 (0.30) | GABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118265706-A | CDK2 inhibitors and methods of making and using the same | 缆图药品公司 | 2024-06-28 | — | — | CN | disclosed |
| WO-2023092088-A1 | CDK2 INHIBITORS AND METHODS OF MAKING AND USING SAME | BLUEPRINT MEDICINES CORPORATION (US) | 2023-05-25 | — | — | WO | disclosed |
| WO-2023092107-A1 | CDK2 INHIBITORS AND METHODS OF MAKING AND USING SAME | BLUEPRINT MEDICINES CORPORATION (US) | 2023-05-25 | — | — | WO | disclosed |
| US-20210198239-A1 | COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2021-07-01 | — | — | US | disclosed |
| US-11014911-B2 | CDK2 inhibitors | PFIZER INC. (US) | 2021-05-25 | — | — | US | disclosed |
| WO-2020157652-A2 | CDK2 INHIBITORS | PFIZER INC. (US) | 2020-08-06 | — | — | WO | disclosed |
| US-20200247784-A1 | CDK2 INHIBITORS | PFIZER INC. (US) | 2020-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198239-A1 | COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR | ENTPD5, ADORA2A, ENTPD1 | LMNA 1383/4885GABRA1 1184/4885ALDH1A1 216/4885 |
| US-20200247784-A1 | CDK2 INHIBITORS | CDK2, CDK1, CCNI | LMNA 1764/4885GABRA1 4673/4885ALDH1A1 2447/4885 |
| US-11014911-B2 | CDK2 inhibitors | CDK2, CDK1, CCNI | LMNA 1764/4885GABRA1 4673/4885ALDH1A1 2447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.